Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05519085 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Celgene.

Recruiting
Registry status
Phase 3
Development phase
810
Enrollment target
20
Study locations

NCT05519085: Recruiting Phase 3 study of Relapsed or Refractory Multiple Myeloma, sponsored by Celgene.

NCT05519085 is a Phase 3 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by Celgene. The registered enrollment target is 810 participants, above the 261-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (210% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05519085, a Phase 3 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Celgene.

RECRUITING
Registry status
Phase 3
Development phase
810 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Conditions Studied

Relapsed or Refractory Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Pomalidomide
  • DRUG Bortezomib
  • DRUG mezigdomide

Study Locations (20)

Florida

  • Advanced Research - Coral Springs
  • Florida Cancer Specialists - South - Fort Myers
  • Florida Cancer Specialists - North - St. Petersburg
  • Florida Cancer Specialists - East - West Palm Beach

California

  • Cancer and Blood Specialty Clinic - Los Alamitos
  • Sharp Memorial Hospital - San Diego
  • Local Institution - 0273 - West Hollywood

Louisiana

  • Our Lady of the Lake RMC - Baton Rouge
  • Local Institution - 0255 - New Orleans
  • Local Institution - 0385 - Shreveport

Connecticut

  • UConn Health - Farmington
  • Local Institution - 0208 - New Haven

Georgia

  • University Cancer Blood Ctr - Athens
  • Local Institution - 0048 - Marietta

Kansas

  • Local Institution - 0330 - Garden City
  • University of Kansas Medical Center - Westwood

Colorado

  • Local Institution - 0381 - Aurora

Maryland

  • Sinai Hospital Of Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 810 participants
Start Date 2022-09-20
Est. Completion 2033-11-30
Phase Phase 3
Celgene

308 total trials

What NCT05519085 shows while recruiting

NCT05519085 is an interventional study that assigns participants to a tested intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap, above the 261-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (210% higher).

The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.

NCT05519085 names 20 study sites across 10 states, led by Florida, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05519085 about?

NCT05519085 is a clinical study titled "A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)". The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of ther...

What is the current status of trial NCT05519085?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 810 participants. The study started on 2022-09-20. Estimated completion is 2033-11-30.

What conditions does trial NCT05519085 study?

This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.

What interventions are being tested in trial NCT05519085?

The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), mezigdomide (DRUG).

Who is sponsoring clinical trial NCT05519085?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05519085 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed or Refractory Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05519085's enrollment target sits among peer trials

810 2nd of 10 the highest of 10 other Relapsed or Refractory Multiple Myeloma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Relapsed or Refractory Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06529094 · 808 participants · NA

    Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

  • NCT07218029 · 815 participants · Phase 3

    A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05519085

Source: ClinicalTrials.gov NCT05519085, the US trial registry maintained by the National Library of Medicine. NCT05519085 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.